Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT04937166
A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies
- NCT04937166 ↗
- Terminated
- Kahr Medical
- Focused
We haven't built an HCP commentary report on NCT04937166 (DSP107 plus azacitidine; DSP107 plus azacitidine plus venetoclax in acute myeloid leukemia, myelodysplastic syndromes, chronic myelomonocytic leukemia) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04937166 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- An Open-label Phase Ib Study of DSP107 for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Acute Myeloid Leukemia; Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia
- Interventions
- DSP107; Azacitidine; Venetoclax
- Arms
- DSP107 in combination with azacitidine or azacitidine plus venetoclax. · Experimental
- Enrollment
- 25
- Primary outcomes
- Adverse Events (AEs)
- Dose Limiting Toxicities (DLT)
- Response Rate (RR) including Complete Remission (CR) and Complete Remission with Incomplete Blood Count Recovery (CRi)
- Sponsor
- Kahr Medical
- Start
- Jan 13, 2022
- Primary completion
- Apr 23, 2025
- Results posted
- No
- Registry record
- NCT04937166 · updated Nov 10, 2025